The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial of preoperative radiotherapy (RT) and panitumumab (PAN) in KRAS wild type (wt) rectal cancer (RC).
Feby Ingriani Mardjuadi
No relevant relationships to disclose
Jean-Luc Canon
No relevant relationships to disclose
Jean-Charles Coche
No relevant relationships to disclose
Anne Jouret-Mourin
No relevant relationships to disclose
Christine Sempoux
No relevant relationships to disclose
Jean-Charles Goeminne
No relevant relationships to disclose
Thierry Delaunoit
No relevant relationships to disclose
Javier Carrasco
No relevant relationships to disclose
Peter Vuylsteke
No relevant relationships to disclose
Yves Humblet
No relevant relationships to disclose
Nicolas Meert
No relevant relationships to disclose
Marc Van den Eynde
No relevant relationships to disclose
Anne Moxhon
No relevant relationships to disclose
Jean-Pascal H. Machiels
Consultant or Advisory Role - Boehringer Ingelheim